56 drugs reach their earliest generic-entry date in 2040

Jan 2040 · 5

Drug	Ingredient	Applicant	NDA	Earliest generic entry	Basis
Tymlos abaloparatide	abaloparatide	Radius	208743	10 Jan 2040	patent, carve-out possible
Elucirem · 7 strengths gadopiclenol	gadopiclenol	Guerbet	216986	17 Jan 2040	patent
Ephedrine Sulfate · 2 strengths ephedrine sulfate	ephedrine sulfate	Ph Health	213994	22 Jan 2040	patent
Furoscix Readyflow (Autoinjector) furosemide	furosemide	Scpharmaceuticals	209988	30 Jan 2040	patent
Sympazan · 3 strengths clobazam	clobazam	Cosette	210833	31 Jan 2040	patent

Feb 2040 · 10

Drug	Ingredient	Applicant	NDA	Earliest generic entry	Basis
Lipfendra enlicitide decanoate	enlicitide decanoate	Msd	220848	4 Feb 2040	patent
Dyanavel Xr 10 amphetamine; amphetamine aspartate/dextroamphetamine sulfate	amphetamine; amphetamine aspartate/dextroamphetamine sulfate	Tris Pharma Inc	210526	11 Feb 2040	patent, carve-out possible
Dyanavel Xr 15 amphetamine; amphetamine aspartate/dextroamphetamine sulfate	amphetamine; amphetamine aspartate/dextroamphetamine sulfate	Tris Pharma Inc	210526	11 Feb 2040	patent, carve-out possible
Dyanavel Xr 20 amphetamine; amphetamine aspartate/dextroamphetamine sulfate	amphetamine; amphetamine aspartate/dextroamphetamine sulfate	Tris Pharma Inc	210526	11 Feb 2040	patent, carve-out possible
Dyanavel Xr 5 amphetamine; amphetamine aspartate/dextroamphetamine sulfate	amphetamine; amphetamine aspartate/dextroamphetamine sulfate	Tris Pharma Inc	210526	11 Feb 2040	patent, carve-out possible
Livmarli maralixibat chloride	maralixibat chloride	Mirum	214662	12 Feb 2040	patent, carve-out possible
Danziten · 2 strengths nilotinib tartrate	nilotinib tartrate	Azurity	219293	18 Feb 2040	patent
Spravato esketamine hydrochloride	esketamine hydrochloride	Janssen Pharms	211243	18 Feb 2040	patent, carve-out possible
Airduo Respiclick · 3 strengths fluticasone propionate; salmeterol xinafoate	fluticasone propionate; salmeterol xinafoate	Teva Pharm	208799	20 Feb 2040	patent
Brinsupri · 2 strengths brensocatib	brensocatib	Insmed Inc	217673	21 Feb 2040	patent

Mar 2040 · 2

Drug	Ingredient	Applicant	NDA	Earliest generic entry	Basis
Konvomep omeprazole; sodium bicarbonate	omeprazole; sodium bicarbonate	Azurity	213593	1 Mar 2040	patent, carve-out possible
Recorlev levoketoconazole	levoketoconazole	Strongbridge	214133	2 Mar 2040	patent, carve-out possible

Apr 2040 · 3

Drug	Ingredient	Applicant	NDA	Earliest generic entry	Basis
Ayvakit · 2 strengths avapritinib	avapritinib	Blueprint Medicines	212608	10 Apr 2040	patent
Xipere triamcinolone acetonide	triamcinolone acetonide	Bausch And Lomb Inc	211950	16 Apr 2040	patent
Imkeldi imatinib mesylate	imatinib mesylate	Shorla Oncology	219097	27 Apr 2040	patent

May 2040 · 9

Drug	Ingredient	Applicant	NDA	Earliest generic entry	Basis
Orladeyo · 2 strengths berotralstat dihydrochloride	berotralstat dihydrochloride	Biocryst	214094	1 May 2040	patent
Orladeyo · 4 strengths berotralstat dihydrochloride	berotralstat dihydrochloride	Biocryst	219776	1 May 2040	patent
Duvyzat givinostat hydrochloride	givinostat hydrochloride	Italfarmaco Spa	217865	3 May 2040	patent
Wegovy Flextouch semaglutide	semaglutide	Novo	215256	13 May 2040	patent, carve-out possible
Emerphed · 2 strengths ephedrine sulfate	ephedrine sulfate	Nexus	213407	16 May 2040	patent
Scemblix · 3 strengths asciminib hydrochloride	asciminib hydrochloride	Novartis	215358	17 May 2040	patent, carve-out possible
Ambelvist · 6 strengths gadoquatrane	gadoquatrane	Bayer Healthcare	219627	19 May 2040	patent
Sofdra sofpironium bromide	sofpironium bromide	Botanix Sb	217347	22 May 2040	patent
Subvenite lamotrigine	lamotrigine	Owp Pharms	218879	29 May 2040	patent

Jun 2040 · 4

Drug	Ingredient	Applicant	NDA	Earliest generic entry	Basis
Motpoly Xr · 3 strengths lacosamide	lacosamide	Aucta	216185	5 Jun 2040	patent
Vyalev foscarbidopa; foslevodopa	foscarbidopa; foslevodopa	Abbvie	216962	10 Jun 2040	patent, carve-out possible
Nexletol bempedoic acid	bempedoic acid	Esperion Theraps Inc	211616	19 Jun 2040	patent
Nexlizet bempedoic acid; ezetimibe	bempedoic acid; ezetimibe	Esperion Theraps Inc	211617	19 Jun 2040	patent

Jul 2040 · 3

Drug	Ingredient	Applicant	NDA	Earliest generic entry	Basis
Agamree vamorolone	vamorolone	Catalyst Pharms	215239	16 Jul 2040	patent
Qamzova meloxicam	meloxicam	Nanjing Delova	217593	19 Jul 2040	patent
Genosyl nitric oxide	nitric oxide	Vero Biotech Inc	202860	22 Jul 2040	patent, carve-out possible

Aug 2040 · 8

Drug	Ingredient	Applicant	NDA	Earliest generic entry	Basis
Ingrezza · 3 strengths valbenazine tosylate	valbenazine tosylate	Neurocrine	209241	10 Aug 2040	patent, carve-out possible
Ingrezza Sprinkle · 3 strengths valbenazine tosylate	valbenazine tosylate	Neurocrine	218390	10 Aug 2040	patent, carve-out possible
Alyftrek deutivacaftor; tezacaftor; vanzacaftor calcium	deutivacaftor; tezacaftor; vanzacaftor calcium	Vertex Pharms Inc	218730	13 Aug 2040	patent
Kygevvi doxecitine; doxribtimine	doxecitine; doxribtimine	Ucb Inc	219792	19 Aug 2040	patent
Eprontia topiramate	topiramate	Azurity	214679	21 Aug 2040	patent
Oriahnn (Copackaged) elagolix sodium,estradiol,norethindrone acetate; elagolix sodium	elagolix sodium,estradiol,norethindrone acetate; elagolix sodium	Abbvie	213388	27 Aug 2040	patent, carve-out possible
Orilissa · 2 strengths elagolix sodium	elagolix sodium	Abbvie	210450	27 Aug 2040	patent, carve-out possible
Arynta lisdexamfetamine dimesylate	lisdexamfetamine dimesylate	Azurity	219847	30 Aug 2040	patent

Sep 2040 · 2

Drug	Ingredient	Applicant	NDA	Earliest generic entry	Basis
Liletta levonorgestrel	levonorgestrel	Medicines360	206229	7 Sep 2040	patent
Lumakras · 3 strengths sotorasib	sotorasib	Amgen Inc	214665	15 Sep 2040	patent, carve-out possible

Oct 2040 · 3

Drug	Ingredient	Applicant	NDA	Earliest generic entry	Basis
Cabenuva Kit · 2 strengths cabotegravir; rilpivirine	cabotegravir; rilpivirine	Viiv Hlthcare	212888	1 Oct 2040	patent, carve-out possible
Pemazyre · 3 strengths pemigatinib	pemigatinib	Incyte Corp	213736	3 Oct 2040	patent
Fyarro sirolimus	sirolimus	Aadi	213312	28 Oct 2040	patent

Nov 2040 · 2

Drug	Ingredient	Applicant	NDA	Earliest generic entry	Basis
Cosela trilaciclib dihydrochloride	trilaciclib dihydrochloride	Pharmacosmos	214200	13 Nov 2040	patent
Yeztugo lenacapavir sodium	lenacapavir sodium	Gilead Sciences Inc	220018	25 Nov 2040	patent, carve-out possible

Dec 2040 · 5

Drug	Ingredient	Applicant	NDA	Earliest generic entry	Basis
Ojjaara · 3 strengths momelotinib dihydrochloride	momelotinib dihydrochloride	Glaxosmithkline	216873	2 Dec 2040	patent, carve-out possible
Journavx suzetrigine	suzetrigine	Vertex Pharms Inc	219209	4 Dec 2040	patent
Caplyta · 3 strengths lumateperone tosylate	lumateperone tosylate	Intra-Cellular	209500	10 Dec 2040	patent
Cabtreo adapalene; benzoyl peroxide; clindamycin phosphate	adapalene; benzoyl peroxide; clindamycin phosphate	Bausch	216632	28 Dec 2040	patent
Mycapssa octreotide acetate	octreotide acetate	Chiesi	208232	28 Dec 2040	patent, carve-out possible